Alder BioPharmaceuticals® reports 12-month data of eptinezumab in PROMISE 1 phase 3 trial
Alder announced new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. The data demonstrated that patients experienced further reductions in migraine following the third and fourth quarterly infusions at both dose levels (100mg and 300mg) of eptinezumab. April 24, 2018